Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA in Borderline Personality Disorder
NCT06683014Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midomafetamine in borderline personality disorder (BPD), sponsored by Yale University. Started Sep 2025; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT06683014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683014.